Is A New Oral PCSK9 Inhibitor A Major Therapeutic Breakthrough? YES
Enlicitide demonstrated substantial lipid-lowering efficacy with an acceptable safety profile. The ongoing CORALreef Outcomes trial will determine whether these lipid improvements translate into reductions in major adverse cardiovascular events.
Sep 4th, 2026